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Abstract: Hypoxia can induce chemoresistance, which is a significant clinical obstacle in cancer
therapy. Here, we assessed development of hypoxia-induced chemoresistance (HICR) against
free versus polymeric cisplatin micelles in a triple negative breast cancer cell line, MDA-MB-231.
We then explored two strategies for the modulation of HICR against cisplatin micelles: a) the
development of actively targeted micelles; and b) combination therapy with modulators of HICR in
MDA-MB-231 cells. Actively targeted cisplatin micelles were prepared through surface modification
of acetal-poly(ethylene oxide)-poly(α-carboxyl-ε-caprolactone) (acetal-PEO-PCCL) micelles with
epidermal growth factor receptor (EGFR)-targeting peptide, GE11 (YHWYGYTPQNVI). Our results
showed that hypoxia induced resistance against free and cisplatin micelles in MDA-MB-231 cells.
A significant increase in micellar cisplatin uptake was observed in MDA-MB-231 cells that overexpress
EGFR, following surface modification of micelles with GE11. This did not lead to increased
cytotoxicity of micellar cisplatin, however. On the other hand, the addition of pharmacological
inhibitors of key molecules involved in HICR in MDA-MB-231 cells, i.e., inhibitors of hypoxia
inducing factor-1 (HIF-1) and signal transducer and activator of transcription 3 (STAT3), substantially
enhanced the cytotoxicity of free and cisplatin micelles. The results indicated the potential
benefit of combination therapy with HIF-1 and STAT3 inhibitors in overcoming HICR to free or
micellar cisplatin.
Keywords: hypoxia-induced chemoresistance; cisplatin; polymeric micelle; EGFR-targeted therapy;
STAT3; HIF-1; GE11 peptide; pharmacological Inhibitors of HIF-1 and STAT3; combination therapy
1. Introduction
Hypoxia is a common feature of solid tumors. Hypoxic areas in tumors are defined as regions
with lower oxygen (O2) levels than physiological oxygen concentrations [1]. Hypoxia arises when the
need for oxygen exceeds its supply. Hypoxia-induced chemoresistance (HICR) has been observed in a
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number of human cancers, including triple negative breast cancer (TNBC) [2–5], the most deadly and
therapy-resistant type of breast cancer [6]. The development of HICR in TNBC is a significant clinical
obstacle against effective cancer therapy. This necessitates the development of new strategies that can
prevent or overcome HICR in TNBC.
Cisplatin is a platinum drug used as part of a standard chemotherapy regimen in TNBC
patients [7,8]. However, its use in cancer patients leads to the emergence of severe side effects including
renal damage, deafness, and peripheral neuropathy. The use of nanocarriers has been extensively
studied in recent decades as a means to attenuate the toxic side effects of anticancer agents. Several
different nanocarriers of cisplatin have been reported in the literature, from which a few have found
their way to clinical trials [9]. The developed nano-formulations have been mostly effective in lowering
the side effects of cisplatin in preclinical models. However, they failed to potentiate the anticancer
effects of drug [10,11].
Reports on the effect of nano-delivery of anticancer drugs on HICR are limited. This is of
particular interest, as delivery of anticancer drugs by their nano-formulations may, in fact, restrict
drug access and movement to hypoxic regions of the tumor where resistant cancer cells may be
present. To circumvent the problem of nano-formulation penetration to hypoxic regions of solid
tumors, incorporation of nanoparticles in non-malignant cells that display inherent hypoxia-targeting
abilities, such as monocytes, macrophages or even neural stem cells [12,13], or modification of the
surface of nanoparticles by tumor-penetrating peptides has been tried by different research groups [14].
These strategies sought to enhance the penetration of nano-drug delivery systems at the solid tumor at
a tissue level.
This study aimed to study the effect of cisplatin delivery by a stealth nano-formulation on HICR
at a cellular level and explore strategies to circumvent HICR. For this purpose, we used a previously
reported polymeric micellar formulation for cisplatin developed by our group [15] and assessed
the cytotoxicity of cisplatin as part of this formulation versus free drug in normoxic versus hypoxic
MDA-MB-231 cells. We then explored two strategies for the modulation of hypoxia-induced cisplatin
resistance in the same cell line; first, by active targeting of cisplatin micelles to MDA-MB-231 cells, to
enhance intracellular cisplatin levels, and second, by combining cisplatin or its nano-formulations
with modulators of HICR in MDA-MB-231 cells.
For the purpose of active drug targeting, we chose modification of polymeric micellar cisplatin
with peptide ligands against epidermal growth factor receptor (EGFR), since coexistence of hypoxia
and high levels of EGFR expression is a known feature of TNBC [16,17]. We postulated the high
expression of EGFR on the hypoxic TNBC cells can be exploited to achieve enhanced delivery of cancer
therapeutics to the cells [17,18].
Targeted nanocarriers can significantly improve drug performance by delivering a high payload
of drug to cancer cells [19–22]. Previous studies have provided support for the use of EGFR
monoclonal antibody for the development of ligand guided nanocarriers for the purpose of tumor
imaging or targeted drug delivery [23–27]. The high molecular weight of the full-length antibody,
however, may compromise the penetration of antibody modified nanocarriers into tumor tissue,
particularly in hypoxic tumor regions. It may also enhance the chance of nanocarrier removal by
the reticuloendothelial system following opsonization in the blood circulation [28]. Furthermore, the
high cost of the full-length antibody and limitations on the use of organic solvents for its conjugation
to the surface of nanocarriers prohibits the wide use of antibodies as ligands for tumor-targeted
nanocarriers. In this context, use of an EGFR-specific peptide, GE11, may be a better option. GE11
is a 12-residue peptide (YHWYGYTPQNVI) which was originally developed using phage display
technique [29]. GE11 peptide shows a lower affinity for EGFR than its natural ligand, EGF, however,
it provides the advantage of lower mitogenic activity. Overall, due to its high EGFR affinity, minimum
immunogenicity, and relatively cheap method of synthesis and scale-up, GE11 has been widely
conjugated to a variety of nanocarriers, including liposomes, polymeric micelles, as well as gold and
gelatin nanoparticles [28,29].
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In this study, we developed GE11 modified polymeric micellar complexes of cisplatin and assessed
the success of this approach in enhancing cellular delivery of cisplatin and overcoming HICR to
cisplatin in a TNBC associated cell line, i.e., MDA-MB-231 cells. We then investigated the effect of
adding pharmacological inhibitors of hypoxia inducing factor-1 (HIF-1) and signal transducer and
activator of transcription 3 (STAT3), as the key modulators of HICR in this cell line [4,30], on anticancer
activity of polymeric micellar formulations of cisplatin versus free drug.
2. Materials and Methods
2.1. Materials
Cisplatin (cis-diamminedichloroplatinum(II) (CDDP) (purity 99%), #H878, was purchased from,
AK Scientific Inc., Union City, CA, USA. Methoxy-PEO 5000 (MePEO), sodium cyanoborohydride,
and Stattic were obtained from Sigma, St Louis, MO, USA. Stannous octoate was dried
and purified using anhydrous magnesium sulfate, dry toluene, and vacuum distillation [31].
α-Benzylcarboxylate-ε-caprolactone (BCL) was synthesized by Alberta Research Chemicals Inc. (ARCI,
Edmonton, AB, Canada) based on methods published previously by our group [32]. All other chemicals
and reagents used were of analytical grade.
2.1.1. Synthesis of Block Copolymers with Functionalized Poly(ethylene oxide) (PEO)
Acetal-poly(ethylene oxide) (acetal-PEO) was synthesized based on the previously published
method by Nagasaki et al. [33]. Briefly, potassium naphthalene, the catalyst, was freshly prepared
before the synthesis of acetal-PEO. To prepare the catalyst, 1.65 g (12.9 mmol) naphthalene and 0.575 g
(14.7 mmol) potassium were added into 50 mL anhydrous tetrahydrofuran (THF). The reaction was
protected under dry argon gas and kept running for 24 h, until a dark green color was obtained.
To prepare acetal-PEO, 0.3 mL (2 mmol) 3,3-diethoxy propanol, the initiator, was first added into 40 mL
anhydrous THF in a three-neck round bottom flask. The flask was purged with dry argon gas and
maintained under an argon atmosphere. The catalyst solution (7 mL, ∼2 mmol) was added dropwise
into the reaction solution to activate the initiator. After 10 min of stirring, the flask was transferred into
an ice water bath. Ethylene oxide (11.4 mL, 228 mmol) was added into the reaction solution. After 48 h,
the reaction was quenched by acidified ethanol (2 mL). Acetal-PEO was recovered by precipitation
in ethyl ether. The product was purified by dissolution in THF and precipitation in ethyl ether, and
vacuum dried for further use.
Synthesis of acetal-PEO-poly-(ε-caprolactone) (acetal-PEO-PCL) and acetal-PEO-poly(α-benzyl
carboxylate-ε-caprolactone) (acetal-PEO-PBCL) block copolymers has been described in our previous
publications in detail [34]. Acetal-PEO-PBCL was first prepared through ring opening bulk
polymerization of BCL with acetal-PEO as an initiator. This was followed by hydrogen reduction
of PBCL block catalyzed by Pd/charcoal. Briefly, 600 mg (0.1 mmol) acetal-PEO was reacted with
500 mg (2 mmol) BCL under vacuum at 145 ◦C for 6 h using stannous octoate as catalyst. Then
the benzyl groups on acetal-PEO-PBCL were removed through hydrogen reduction in anhydrous
THF catalyzed by Pd/charcoal. The produced acetal-PEO-PCCL was recovered and purified by
precipitation in hexane.
2.1.2. Synthesis of GE11 Peptide and GE11 Conjugation to Poly(ethylene
oxide)-poly(α-carboxyl-ε-caprolactone) (PEO-PCCL) Block Copolymers
The GE11 peptide (NH2-YHWYGYTPQNVI-COOH) (Figure S1a) was synthesized chemically
using standard Fmoc solid phase peptide synthesis as described previously by the laboratory of
Kaur et al. [35]. Briefly, the first amino acid, isoleucine, was coupled to a 2-chlorotrityl resin (0.1 mM)
(NovaBiochem, San Diego, CA, USA) at 5-fold excess using the N,N diisopropyl ethylamine (DIPEA) at
room temperature for 5 h. Further amino acids were added automatically using an automated peptide
synthesizer (Tribute, Protein Technology, Inc., Tucson, AZ, USA). The completed peptide was ultimately
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released from the resin with a mixture of 90% trifluoroacetic acid (TFA), 9% dichloromethane, and
1% triisopropylsilane (∼10 mL) for 90 min at room temperature. The cleaved peptide combined with
TFA was then concentrated, washed with diethyl ether, dissolved in water and purified. Purification
was done using C18 semi-preparative (1 cm × 25 cm, 5 µm) reverse-phase high-pressure liquid
chromatography (HPLC) (Varian Prostar, MD, USA) with a gradient of acetonitrile−H2O (10−70%
containing 0.05% TFA, 2 mL/min, 45 min run time). The peptide solution was freeze-dried to give
pure peptide as a white powder. Analytical (0.46 cm × 25 cm, 5 µm) HPLC revealed a purity of 97%
at 220 nm with retention time (Rt) = 13 min, and the MALDITOF (Voyager spectrometer, Applied
Biosystems, Foster City, CA, USA) mass analysis showed [M + H]+ for the peptide as 1541.6 (calculated
1540.7) (Figure S1b).
The GE11 peptide was conjugated to the micellar surface through a reaction with the functional
acetal groups on the micellar shell [34]. First, acetal-PEO6000-PCCL3000 (with 87% reduction of PBCL to
PCCL) was assembled into polymeric micelles. Briefly, a diblock copolymer of acetal-PEO6000-PCCL3000
(20 mg) was dissolved in 1 mL acetone and added dropwise to 4 mL water while stirring. The solution
was stirred for 24 h under a fume hood to remove acetone by evaporation. On the following day,
the aqueous solution of polymeric micelles was acidified to pH 2 with 0.5 M HCl and stirred for 1 h at
room temperature to produce aldehyde modified polymeric micelles. The resulting solution was then
neutralized with 0.5 M NaOH. The osmolarity of the micellar solution was adjusted by addition of an
appropriate volume of concentrated 10X P phosphate-buffered saline (PBS). An aqueous solution of
the peptide (1.95 mg peptide in 500 µL of 1% dimethyl sulfoxide (DMSO)) (1:2 peptide to polymer,
mole:mole ratio) was added and incubated with the aldehyde bearing micelles at room temperature for
2 h under moderate stirring. Subsequently, sodium cyanoborohydride (NaBH3CN) (1 mg) was added
to the polymer to reduce the Schiff’s base. After 48 h of reaction, the unreacted peptide and reducing
agent were removed by extensive dialysis using Spectrapor, MWCO 3500 (Spectrum Laboratories, Inc.,
Rancho Dominguez, CA, USA) against distilled water (24 h). The conjugation efficiency of the peptide
to polymeric micelle was assessed by gradient reversed phase HPLC method measuring unreacted
peptide concentration. A µ Bondpack (Waters Corp., Milford, MA, USA) C18 analytical column (10 µm
3.9 × 300 mm) was used. Gradient elution was performed at a flow rate of 1 mL/min using a Varian
Prostar 210 HPLC System. Detection was performed at 214 nm using a Varian 335 detector (Varian Inc.,
Mulgrave, Australia). The mobile phase consisted of 0.1% TFA in H2O (solution A) and acetonitrile
(solution B). The mobile phase was programmed as follows: (1) 100% A for 1 min, (2) linear gradient
from 100% A to 60% A in 20 min, (3) linear gradient from 60% A to 0% A in 4 min, (4) 0% A for 2 min, (5)
linear gradient from 0% A to 100% A in 4 min, and (6) 100% A for 5 min. The concentration of unreacted
peptide was calculated based on a calibration curve for the peak height of known concentrations of
GE11 peptide in aqueous solution of 1% DMSO. The amount of conjugated peptide was calculated by
subtracting the amount of unreacted peptide from the initial peptide added to the reaction. The peptide
conjugated polymer was then freeze-dried until further use. 1H NMR was performed on a Bruker,
ASENDTM 600 MHz spectrometer (Billerica, MA, USA) to confirm the conjugation of the GE11 peptide
on PEO-PCCL block polymer. Samples (GE11 peptide, acetal-PEO-PCCL, and GE11-PEO-PCCL)
were dissolved in deuterated DMSO at a concentration range of 3–5 mg/mL and 1H NMR spectra
were generated.
2.1.3. Preparation of Plain and GE11 Cisplatin Micelles
GE11-PEO-PCCL or PEO-PCCL block copolymers were assembled into cisplatin polymeric
micelles as reported previously with slight modification [15]. Briefly, either of the diblock copolymer
(20 mg) was mixed with 4 mL aqueous solution of cisplatin (20 mg) and sodium bicarbonate (4–5 mg).
The mixture was stirred for 24 h at room temperature. We couldn’t dissolve the whole amount
of cisplatin in such volume, but high cisplatin levels were identified to be required to enhance
complexation with the polymer and increase its loading levels. After micelle preparation, initially
using centrifugation, the undissolved portion of cisplatin was separated from the micellar solution.
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In the next step, the unbound cisplatin was removed by ultrafiltration (3600× g for 40 min) using
Centricon® plus centrifugal filter units (MWCO 3 KDa, Millipore, Billerica, MA, USA) and micelles
were re-suspend in 4 mL doubly distilled water. The final concertation of cisplatin was determined
using ion coupled plasma mass spectrometer (ICP-MS).
2.1.4. Measurement of the Size and Zeta Potential of Plain and GE11 Cisplatin Micelles
The average hydrodynamic diameter and size distribution of the GE11 cisplatin micelles were
estimated and compared to plain cisplatin micelles by dynamic light scattering (DLS) using Malvern
Zetasizer (Nano ZEN3600, Malvern, UK). The zeta potential of polymeric micelles was also estimated
using the same equipment.
2.1.5. Measurement of the Critical Micellar Concentration (CMC) of Plain and GE11 Cisplatin Micelles
The CMC of the GE11 cisplatin micelles were estimated and compared to plain cisplatin micelles
by DLS [36] using Malvern Zetasizer (Nano ZEN3600, Malvern, UK). For this purpose, plain and
GE11 cisplatin micelles having polymer concentrations ranging from 1000 to 3 µg/mL were prepared.
Briefly, from a stock solution of 1000 µg/mL micellar solution, different concentrations of micelles were
prepared by serial dilution. The lowest prepared concentration was 3 µg/mL. The intensity of scattered
light for each of concentrations was measured at a scattering angle of 173◦ at 25 ◦C. The average
intensity of scattered light from three measurements was plotted against polymer concentration.
The intersection of the two linear graphs in the sigmoidal curve, i.e., the onset of a rise in the intensity
of scattered light, was defined as the CMC value.
2.1.6. Measurement of Cisplatin Encapsulation
The Pt(II) content in the GE11 cisplatin micelles was determined by ion coupled plasma mass
spectrometer (ICP-MS, Agilent Technologies, Tokyo, Japan). The ICP operated at a radiofrequency
power of 1550 W, and the flow rate of argon carrier gas was 0.9–1.0 L/min. Pt(II) was monitored at
m/z 195. A standard curve in the Pt(II) concentration range of 100, 50, 20, 10, and 1 ppb was generated
using atomic absorption standard. Appropriate dilutions of the test samples were prepared in 1%
nitric acid (HNO3). Data were acquired and processed by ICP-MS ChemStation (Agilent Technologies,
Santa Clara, CA, USA). The encapsulation efficiency (EE) and drug loading (DL) were calculated using
the following equations:
EE (%) =
the amount o f encapsulated cisplatin (mg)
the total f eeding amount o f cisplatin (mg)
× 100
DL (%) =
the amount o f encapsulated cisplatin (mg)
the total amount o f polymer (mg)
× 100
2.1.7. In Vitro Release Studies
The release of free cisplatin and its micellar formulations (plain and GE11 cisplatin micelles) was
measured using equilibrium dialysis method in PBS (pH = 7) and acetate buffer saline (pH = 5). Briefly,
free cisplatin, plain or GE11 cisplatin micelles (4 mL) containing 30 µg/mL cisplatin were placed into
a dialysis bag (Spectrapor, MWCO 3500) in a beaker containing 500 mL PBS or acetate buffer saline.
The release study was performed at 37 ◦C in a Julabo SW 22 shaking water bath (Seelbach, Germany).
At selected time intervals, 100 µL samples were withdrawn from the inside of dialysis bag and replaced
with fresh medium for ICP-MS analysis. The percent cumulative amount of cisplatin released was
calculated and plotted as a function of time. The release profiles of plain and GE11 cisplatin micelles
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were compared using the similarity factor, f2, and the profiles were considered significantly different if
f2 < 50 [37]. The similarity factor, f2, was calculated using the following equation [38].
f2 = 50 × log
[1 +( 1
n
) n
∑
j=1
|Rj− Tj|2
]−0.5
× 100
 (1)
where n is the sampling number, Rj and Tj are the percents released of the reference and test
formulations at each time point j.
2.1.8. Cell Culture
MDA-MB-231 cells was obtained from ATCC (Manassas, VA, USA) and maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (Invitrogen, Karlsruhe, Germany), 100 units/mL
penicillin, and 100 µg/mL streptomycin in a humidified incubator under 95% air and 5% CO2 at 37 ◦C.
For hypoxic conditions, cells were cultured in a CO2 incubator maintained at 94% N2, 5% CO2, and
1% O2.
2.1.9. Flow Cytometric Detection of Apoptosis using Annexin V-FITC and Propidium Iodide
Annexin V-FITC (Fluorescein IsoThioCyanate) and propidium iodide (PI) from BD Biosciences
(FITC Annexin V Apoptosis Detection Kit I, #556547, BD Pharmingen™) was used to measure apoptotic
cells by flow cytometry according to the manufacturer’s instructions. Briefly, both floating and
adherent cells were harvested; adherent cells were collected by adding a warm solution of 10 mM
ethylenediaminetetraacetic acid (EDTA) in PBS. The cells were centrifuged at 500 g for 5 min, washed
with ice-cold 1 PBS twice and re-suspended in 400 µL binding buffer containing 5 µL Annexin V-FITC
and 5 µL PI for 15 min at room temperature in the dark. Fluorescence was induced on a Beckman
Coulter Cytomics Quanta SC MPL flow cytometer (10,000 events per sample). Spectral compensation
was performed using Cell Lab Quanta analysis software (Cell Lab Quanta™ SC MPL, Beckman Coulter,
Mississauga, ON, Canada). The number of viable and apoptotic cells were quantified by events in
the quadrants. The results were expressed as the percentage of apoptotic cells at the early stage
(PI negative and Annexin V positive, lower right quadrant), apoptotic cells at the late stage (PI positive
and Annexin V positive, upper right quadrant), necrotic cells (PI positive and Annexin V negative,
upper left quadrant) and viable cells (PI negative and Annexin V negative, lower left quadrant).
2.1.10. MTT Assay
MDA-MB-231 cells (9 × 103 cells/well) were seeded in 96-well plates overnight, and on the
following day, they were exposed to increasing concentration of cisplatin (free drug/cisplatin micelles)
and then incubated for 48 h under hypoxia or normoxia. For combination therapy, MDA-MB-231
cells (9 × 103 cells/well) were seeded in 96-well plates overnight. On the following day, cells were
treated with Tat-tagged form of cyclic peptide inhibitor of HIF-1 (cyclo-CLLFVY) named P1 (50 µM per
well) [39] or Stattic (2 µM per well), or combination of P1 and Stattic for 4 h under normoxia, to give a
final concentration of 2 µM and 50 µM per well, respectively. After 4 h incubation, cells were treated
with cisplatin (50 µM) (as a free drug, plain cisplatin micelles or GE11 cisplatin micelles) and then
incubated for additional 48 h under hypoxic or normoxic conditions. Cellular viability was assessed by
the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolim bromide (MTT) assay. Briefly, MTT solution
(5 mg/mL) was added to incubated cells for 4 h at 37 ◦C. Then the medium was replaced by DMSO
to dissolve the crystals. Optical density was measured spectrophotometrically using a plate reader
(Synergy H1 Hybrid Reader, Biotek, Winooski, VT, USA) at 570 nm. The cellular activity ratio was
represented relative to control (untreated group, cells with media only).
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2.1.11. Western Blot
To measure the expression level of different proteins, MDA-MB-231 cells (2 × 105 cells/well)
were seeded in 6-well plates overnight. After treatment, cells were washed with cold 1X PBS and
lysed using radioimmunoprecipitation assay buffer (RIPA lysis buffer) that was supplemented with
0.1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), a protease Inhibitor Cocktail Set III,
Animal-Free–Calbiochem (#535140, Millipore), and a phosphatase Inhibitor Cocktail Set II (#524625,
Millipore). The lysate was then incubated on ice for 30 min, which was followed by centrifugation at
17,000× g for 20 min to remove genomic DNA. Protein quantification was made by the bicinchoninic
acid (BCA) protein assay kit (Pierce, Rockford, IL, USA), and equal amounts of protein (35–40 µg)
were loaded in 4−15% Tris-Glycine gradient gel (#456-1084, Biorad, Pleasanton, CA, USA). After gel
electrophoresis, proteins were transferred to a nitrocellulose membrane. Membranes were probed with
antibodies against phospho-STAT3 (Tyr705) (pSTAT3) (#9131, Cell Signaling Technologies, Danvers,
MA, USA), Total-STAT3 (T-STAT3) (#8768s, Cell Signaling Technologies), EGFR (#2232, Cell Signaling
Technologies), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (#sc-47724, Santa Cruz
Biotechnologies). Proteins were then detected using peroxidase-conjugated anti-mouse IgG (#7076,
Cell Signaling Technologies) or anti-rabbit IgG (#7074, Cell Signaling Technologies) and visualized
by enhanced chemiluminescence (Pierce ECL Western Blotting Substrate, #32106, Thermo Scientific,
Rockford, IL, USA). Representative results of three independent Western blot analyses are shown in
the Figures 4 and 5, Figure S4 and Figure S5.
2.1.12. Cisplatin Cellular Uptake
Cellular uptake of cisplatin was quantified by ICP-MS (Agilent Technologies, Tokyo, Japan).
MDA-MB-231 cells (65 × 104 cells/flask) were seeded in 25 cm2 flasks overnight. Cells were
exposed to free cisplatin or its micellar formulations (plain and GE11 cisplatin micelles) (166 µM)
for 24 h under normoxic and hypoxic conditions. On the following day, the medium was aspirated,
cells were rinsed with cold PBS, detached using trypsin-EDTA, aliquoted in duplicate in 1.5 mL
micro-centrifuge tubes and pelleted by centrifugation at 500× g for 5 min. One of each duplicate
cell pellet was digested with 20% (v/v) HNO3 overnight at 60 ◦C and analyzed for Pt(II) content by
ICP-MS. The other duplicate was lysed using RIPA lysis buffer that was supplemented with 0.1 mM
phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich, St. Louis, MO, USA), a protease Inhibitor
Cocktail Set III, Animal-Free–Calbiochem (#535140, Millipore), and a phosphatase Inhibitor Cocktail
Set II (#524625, Millipore) and quantified for protein content using the BCA protein assay kit (Pierce,
Rockford, IL, USA). The cell uptake was expressed as cisplatin/cell protein (µg)/µg).
2.1.13. Statistical Analysis
The statistical analysis was performed by Graphpad Prism (version 5.00, Graphpad Software Inc.,
La Jolla, CA, USA). Statistical analysis was performed either using unpaired Student’s t test or one-way
ANOVA (analysis of variance) with Tukey post-test analysis. Statistical significance is denoted by
(p < 0.05). All graphs represent the average of at least three independent experiments with triplicates
unless mentioned otherwise in the text, or graphs. Results were represented as the mean ± standard
deviation (SD).
3. Results
3.1. Successful Synthesis of GE11 Conjugated Poly(ethylene
oxide)-poly(α-carboxyl-ε-caprolactone)(PEO-PCCL) Block Copolymer and Its Self-assembly
GE11 showed a conjugation efficiency reaching 70% of an added peptide as quantified by reversed
phase HPLC to the acetal-PEO-PCCL micellar surface (Figure S2). The molar conjugation percent for
GE11 conjugated PEO-PCCL block polymer was∼35%. In other words, for 100 mole block copolymers,
there is around 35 mole conjugated peptide.
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The peptide conjugation was also confirmed by 1H NMR (Figure S3). Signals from 6.5 to 8.5 ppm
in 1H NMR spectra of GE11 peptide correspond to aromatic protons in its structure (n = 20). To calculate
the molar conjugation percent for GE11-conjugated PEO-PCCL block polymer, first, the summation
of integration of peaks from 6.5 to 8.5 ppm in acetal-PEO-PCCL spectra was subtracted from the
summation of integration of peaks from 6.5 to 8.5 ppm in GE11-PEO-PCCL spectra. The obtained
value corresponded to the integration of aromatic hydrogens of GE11 peptide (n = 20). The degree of
conjugation of GE11 was then determined by calculating the peak intensity ratio of methylene protons
of PCCL segment (OCH2CH2CH2CH2 ((COOH)CO): δ = 4.1 ppm) and the value calculated for the
integration of aromatic hydrogens of GE11 peptide. The calculated degree of conjugation was 0.45
which corresponds to 45 mole peptide per 100 mole block copolymers (Figure S3). The calculated
peptide conjugation degree by 1H NMR (0.45 mol/mol) was slightly higher than what was calculated
by HPLC (0.35 mol/mol).
As summarized in Table 1, both plain and GE11 cisplatin micelles showed similar average
diameters around 80 nm with a low polydispersity index. Critical micellar concentration (CMC),
cisplatin encapsulation efficiency and drug loading of both micelles were also comparable. Overall,
both micellar formulations showed similar characteristics, and it appeared as though the presence of
the GE11 peptide did not alter different micellar properties (p > 0.05, Student’s t test).
Table 1. Characteristics of Cisplatin and GE11 Cisplatin Micelles (n = 3).
Micelle a
Average
Diameter± SD
(nm) b
PDI± SD c Zeta potential± SD (mV)
CMC±
SD
(µg/mL) d
EE± SD
(%) e
DL± SD
(%) f
Drug/polymer
± SD
(mol/mol)
Cisplatin plain micelle 84.4 ± 2.6 0.263 ± 0.11 −13.3 ± 1.2 65.1 ± 5.5 12.4 ± 0.99 12.0 ± 1.41 3.93 ± 0.31
GE11 cisplatin micelle 84.1 ± 3.2 0.235 ± 0.18 −13.6 ± 0.95 70.5 ± 7.2 13.0 ± 2.95 15.5 ± 3.53 4.01 ± 0.93
a Plain and GE11 cisplatin micelles consist of PEO6000-PCCL3000 block copolymers. The number shown in the
subscript indicates average number molecular weight of each block determined by 1H NMR spectroscopy. b Z
average measured by dynamic light scattering (DLS). c Average polydispersity index (PDI) of micellar size
distribution measured by DLS. d Measured from the onset of rise in the intensity values of scattered light as a function
of concentration of micelles by DLS. e Encapsulation efficiency (%) = the amount o f encapsulated cisplatin (mg)the total f eeding amount o f cisplatin (mg) × 100.
f Drug loading (%) = the amount o f encapsulated cisplatin (mg)the total amount o f polymer (mg) × 100.
The in-vitro release of cisplatin from both micelles was investigated in phosphate buffered saline
(PBS) (pH = 7.4), and acetate buffered saline (pH = 5.0) using a dialysis method. Both micellar
formulations showed burst release at the early time points (<1 h). The cumulative drug release
appeared to be significantly slower at the later time points (>2 h) as compared to free drug for
both micelles, however (Student’s t test, p < 0.05). As shown in Figure 1a, micellar formulations
showed ∼60% release of cisplatin within 30 min in PBS as compared to ∼80% release of free drug in
the same media. After 48 h, in PBS, ∼85% of the incorporated drug was released from micelles to
media, compared to complete 100% release for free drug. Similar results were obtained for micellar
formulations of cisplatin in acetate buffered saline (pH = 5.0) (Figure 1b) where a significant reduced
drug release was achieved at later time points (>2 h) (Student’s t test, p < 0.05) for micellar cisplatin
compared to free drug. No difference was observed between the release profiles of plain versus GE11
cisplatin micelles in either media (f 2 > 50). Of note, in acetate buffered saline (pH = 5) complete
release of drug after 48 h was seen, whereas only 80% drug was released in PBS at the same time point
(pH = 7.4) (Figure 1b), although the overall profile of drug release did not show a significant difference
between the two pHs (f2 > 50).
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Figure 1. Percent cumulative release profile of cisplatin from plain and GE11 cisplatin micelles at 
different pHs in (a) PBS (pH = 7.4) and (b) acetate buffer saline (pH = 5.0). (*) denotes where the 
cumulative release of free drug appeared to be significantly different from plain and GE11 cisplatin 
micelles at the related time points (p < 0.05, Student’s t test). Data are represented as mean ± SD (n = 3). 
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reduced under hypoxia, as evidenced by a significant decrease in the proportion of late apoptotic 
cells measured by FITC Annexin V/propidium iodide (PI) assay (Figure 2b). The viable proportion of 
cells also showed a significant increase under hypoxic conditions compared to normoxic ones, when 
treated with cisplatin (Figure 2b). Interestingly, the proportion of necrotic cells following treatment 
with cisplatin under hypoxic conditions increased compared to normoxia, pointing to a change in 
the predominant mode of cisplatin-induced cell death under hypoxic conditions. This phenomenon 
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difference between cell responses to micellar versus free cisplatin irrespective of the oxygen content 
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Figure 1. Percent cumulative release profile of cisplatin from plain and GE11 cisplatin micelles at
different pHs in (a) PBS (pH = 7.4) and (b) acetate buffer saline (pH = 5.0). (*) denotes where the
cumulative release of free drug appeared to be significantly different from plain and GE11 cisplatin
micelles at the related time points (p < 0.05, Student’s t test). Data are represented as mean ± SD (n = 3).
3.2. Hypoxia Induces Chemoresistance to Free Cisplatin in MDA-MB-231 Cells
The MDA-MB-231 cells incubated under hypoxic conditions were shown to be less sensitive
to cytotoxic effects of cisplatin as measured b MTT assay. Cells cultured under hypoxia had a
significantly higher number of colonies surviving cisplatin treatment than cells grown under normoxic
conditio s, as well (Figure 2a). More ver, apoptosis induced by cisplatin was significantly reduced
under hypoxia, as evidenced by a significant decrease in the proportion of late a optotic cells measured
by FITC Annexin V/propidium iodide (PI) assay (Figure 2b). The viable prop rtion of cells also showed
a significant increase under hypoxic conditions compared to normoxic ones, when treated with cisplatin
(Figure 2b). Interestingly, the proportion of necrotic cells foll wing treatment with cisplatin under
hypoxic conditions i creased compared to ormoxia, pointing to a change in the predominant mode
of cisplatin-i duced cell death under hypoxic conditions. This phen menon was also previously
reporte for prostate carcinoma [40]. Similar to observation on free cisplatin (Figure 3a), we found
less sensitivity towards polymeric micellar cisplatin in MDA-MB-231 cells cultured under hy oxic
conditions by MTT assay (Figure 3b,c). There was also no significant difference between cell responses
to micellar versus free cisplatin irrespective of the oxygen content for cell culture (one-way ANOVA
with Tukey post-test, p > 0.05).
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Figure 2. Hypoxia confers chemoresistance to free cisplatin in MDA-MB-231 cells. (a) Colony 
formation ability was assessed for cells treated with cisplatin (8.3 μM) after 24 h incubation under 
normoxic or hypoxic conditions. Cells were then re-plated at a density of 500 cells/well in duplicate 
in six-well plates under normoxia. The number of colonies formed from 500 cells after 7 days was 
graphed. (b) Cisplatin induced-apoptosis under normoxic and hypoxic conditions was measured by 
flow cytometric analysis of Fluorescein IsoThioCyanate (FITC) Annexin V staining in a buffer 
containing propidium iodide. MDA-MB 231 cells were left untreated or treated with increasing 
concentrations of cisplatin for 48 h. Flow cytometry analysis showed different populations of (Q1) 
necrotic or already dead cells (PI positive), (Q2) cells in end-stage apoptosis (FITC Annexin V and PI 
positive), (Q3) viable cells (FITC Annexin V and PI negative), and (Q4) cells in early stage of 
apoptosis (FITC Annexin V positive and PI negative). 2D plot is representative of cells treated with 
cisplatin (33 μM) under normoxia for 48 h. Data are represented as mean ± SD (n = 3). (*) denotes a 
significant difference between hypoxic and normoxic groups at each individual concentration 
(Student’s t test, p < 0.05). 
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Figure 3. Hypoxia confers chemoresistance to free and micellar formulations of cisplatin in 
MDA-MB-231 cells. Viability of MDA-MB-231 cells was measured by MTT assay for cells treated 
with increasing concentrations of (a) free cisplatin; (b) plain cisplatin micelles and (c) GE11 cisplatin 
micelles under hypoxic or normoxic conditions for 48 h. (*) denotes a significant difference between 
groups at each individual concentration (Student’s t test, p < 0.05). 
3.3. Modification of Cisplatin Micelles with GE11 Peptide Enhances the Cellular Uptake of Cisplatin, but Does 
Not Affect its Cytotoxicity in MDA-MB-231 Cells 
Modification of polymeric micelles with EGFR targeting peptide, GE11, was not able to increase 
the cytotoxicity of incorporated cisplatin towards MDA-MB-231 cells under normoxic or hypoxic 
conditions (Figure 3c versus 3b). 
Figure 2. Hypoxia confers chemoresistance to free cisplatin in MDA-MB-231 cells. (a) Colony formati
ability was ssessed for cells treated with cisplatin (8.3 µM) after 24 h incubation under normoxic or
hypoxic conditions. Cells were then re-plated at a density of 500 cells/well in duplicate in six-well lates
under normoxia. The number of colonies formed from 500 cells after 7 days was graphed. (b) Cisplatin
induced-apoptosis under normoxic and hypoxic conditions was measured by flow cytometric analysis
of Fluorescein IsoThioCyanate (FITC) Annexin V staining in a buffer containing propidium iodide.
MDA-MB 231 cells were left untreated or treated with increasing concentrations of cisplatin for 48 h.
Flow cytometry analysis showed different populations of (Q1) necrotic or already dead cells (PI
positive), (Q2) cells in end-stage apoptosis (FITC Annexin V and PI positive), (Q3) viable cells (FITC
Annexin V and PI negative), and (Q4) cells in early stage of apoptosis (FITC Annexin V positive and
PI negative). 2D plot is representative of cells treated with cisplatin (33 µM) under normoxia for 48 h.
Data are represented as mean ± SD (n = 3). (*) denotes a significant difference between hypoxic and
normoxic groups at each individual concentration (Student’s t test, p < 0.05).
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Figur  3. Hy oxia confers chemoresista ce to free and micellar formulations of cisplatin in 
MDA-MB-231 cells. Viability of MDA-MB-231 cells was measured by MTT assay for cells treated 
with increasing concentrations of (a) free cisplatin; (b) plain cisplatin micelles and (c) GE11 cisplatin 
micelles under hypoxic or normoxic conditions for 48 h. (*) denotes a significant difference between 
groups at each individual concentration (Student’s t test, p < 0.05). 
3.3. Modification of Cisplatin Micelles with GE11 Peptide Enhances the Cellular Uptake of Cisplatin, but Does 
Not Affect its Cytotoxicity in MDA-MB-231 Cells 
Modification of polymeric micelles with EGFR targeting peptide, GE11, was not able to increase 
the cytotoxicity of incorporated cisplatin towards MDA-MB-231 cells under normoxic or hypoxic 
conditions (Figure 3c versus 3b). 
Figure 3. Hypoxia confers chemoresistance to free and micellar formulations of cisplatin in
MDA-MB-231 cells. Viability of MDA-MB-231 cells was measured by MTT assay for cells treated
with increasing concentrations of (a) free cisplatin; (b) plain cisplatin micelles and (c) GE11 cisplatin
micelles under hypoxic or normoxic conditions for 48 h. (*) denotes a significant difference between
groups at each individual concentration (Student’s t test, p < 0.05).
3.3. Modification of Cisplatin Micelles with GE11 Peptide Enhances the Cellular Uptake of Cisplatin, but Does
Not Affect its Cytotoxicity in DA-MB-231 Cells
ification of polymeric micelles with EGFR targeting peptid , GE11, w s not able to increas
the cytotoxicity of incorporated cisplatin towards MDA-MB-231 cells under normoxic or hypoxic
conditions (Figure 3c versus 3b).
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This was despite high levels of EGFR expression by MDA-MB-231 cells under normoxic or hypoxic
conditions (Figure 4a) [17], that led to significantly higher cisplatin uptake following modification of
polymeric micelles with GE11 peptide compared to plain micelles under both conditions (Figure 4b).
As shown in Figure 4a, the levels of EGFR expression under hypoxia were time-dependent. At the
24-h time point, there was no significant difference between the expression of EGFR under hypoxia
and normoxia. However, the expression of EGFR was reduced under hypoxia for longer incubation
times. Thus, for the purpose of comparability, we chose the 24-h time point for performing the cell
uptake studies. When we treated the cells with the low concentration of cisplatin, due to multiple
steps of digestion and washing for a sample preparation, we could not quantify the (low) amount
of intracellular cisplatin. To compensate for the limitation of the measurement method, we chose to
treat the cells with a high concentration of cisplatin (166 µM). As shown in Figure 4b, intracellular
levels of cisplatin were found to be significantly reduced under hypoxia for the free drug (∼1.6-fold
decrease) as well as plain cisplatin micelles (∼1.4-fold decrease). Nonetheless, the presence of the
GE11 peptide on micelles appeared to compensate for the hypoxia-mediated reduction in cellular
cisplatin levels. GE11 modified micelles showed similar intracellular drug levels under both hypoxic
and normoxic conditions.
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Figure 4. Modification of cisplatin micelles with GE11 peptide enhances the cellular uptake of 
cisplatin in MDA-MB-231 cells. (a) High levels of epidermal growth factor receptor (EGFR) 
expression under normoxia and hypoxia in MDA-MB-231 cells; (b) The GE11-peptide decoration of 
cisplatin micelles enhanced cellular uptake of cisplatin under hypoxia in MDA-MB-231 cells and 
bridged the gap of its cellular uptake under hypoxia and normoxia. Cisplatin content was measured 
by ion coupled plasma mass spectrometer (ICP-MS) after 24 h treatment of cells with cisplatin (166 
μM) under hypoxia or normoxia. (*) denotes a significant difference between compared groups 
(Student’s t test, p < 0.05). 
3.4. Co-Treatment with Pharmacological Inhibitors of HIF-1 and STAT3 Potentiates the Anticancer Activity of 
Free Cisplatin, as well as Its Micellar Formulations in Hypoxic MDA-MB-231 Cells 
We have previously reported on the role of STAT3 up-regulation under hypoxia as a mediator 
of hypoxia-induced resistance to cisplatin in MDA-MB-231 cells [30,41]. Here, we assessed the 
chemo-sensitizing effect of pharmacological inhibitors of STAT3 and/or HIF-1 (a known mediator of 
hypoxia- induced chemoresistance) in MDA-MB-231 cells treated with different formulations of 
Figure 4. Modification of cisplatin micelles with GE11 peptide enhances the cellular uptake of cisplatin
in MDA-MB-231 cells. (a) High levels of epidermal growth factor receptor (EGFR) expression under
normoxia and hypoxia in MDA-MB-231 cells; (b) The GE11-peptide decoration of cisplatin micelles
enhanced cellular uptake of cisplatin under hypoxia in MDA-MB-231 cells and bridged the gap of its
cellular uptake under hypoxia and normoxia. Cisplatin content was measured by ion coupled plasma
mass spectrometer (ICP-MS) after 24 h treatment of cells with cisplatin (166 µM) under hypoxia or
normoxia. (*) denotes a significant difference between compared groups (Student’s t test, p < 0.05).
3.4. Co-Tr atment with Pharmacological Inhibitors of HIF-1 and STAT3 Potentiates the Anticancer Activity of
Free Cisplatin, as well as Its Micellar Formulations in Hypoxic MDA-MB-231 Cells
We have previously reported on the role of STAT3 up-regulation under hypoxia as a mediator
of hypoxia-induced resistance to cisplatin in MDA-MB-231 cells [30,41]. Here, we assessed the
chemo-sensitizing effect of pharmacological inhibitors of STAT3 and/or HIF-1 (a known i t r
f i - induced chemoresistance) in MDA-MB-231 cells tr ated with diff nt formulations of
cisplatin. For this purp se, a cyclic peptide that inhibits the assembly and function of the HIF-1
transcription factor (cycl -CLLFVY) [39], as well as a known inhibitor of STAT3, i.e., Stattic, [42] were
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used in combination with free, plain and GE11 cisplatin micelles and the cytotoxicity of cisplatin
against MDA-MB-231 cells was measured using MTT assay under normoxic and hypoxic conditions.
The tat-tagged form of cyclo-CLLFVY (named P1), a cyclic peptide which has shown to prevent
the dimerization of HIF-1α/HIF-1β complex by binding to HIF-1α and subsequently inhibit HIF-1
mediated hypoxia response [39,43], was used as a HIF-1 inhibitor. Stattic, a small molecule shown to
inhibit the dimerization and activation of STAT3 mainly through prevention of its phosphorylation [42],
was used as a STAT3 inhibitor. As shown in Figure 5a and Figure S4, successful inhibition of
phosphorylation of STAT3 was achieved in MDA-MB-231 cells using Stattic (2 µM). Both P1 and
Stattic showed minimal non-specific cytotoxicity at their respective effective dose for the inhibition of
HIF-1 and STAT3 (50 and 2 µM, respectively) as shown by MTT assay (Figure 5b).
Under normoxic conditions, co-treatment of MDA-MB-231 cells with P1 and cisplatin formulations
showed a trend towards potentiating the anticancer effect of cisplatin, plain cisplatin micelles or
GE11 cisplatin micelles, as measured by MTT assay, although the difference was not statistically
significant (Figure 5c–e, white bars). However, under hypoxic conditions, combination of P1 with free
cisplatin (Figure 5c, black bars), plain cisplatin micelles (Figure 5d, black bars) and GE11 cisplatin
micelles (Figure 5e, black bars) significantly enhanced the cytotoxicity of cisplatin as part of each
formulation (one-way ANOVA with Tukey post-test, p < 0.05). This was not observed when different
formulations of cisplatin were combined with the inhibitor of STAT3, Stattic, under normoxic conditions
(Figure 5c–e, white bars). Under hypoxia, a combination of Stattic with free cisplatin (Figure 5c, black
bars), plain cisplatin micelles (Figure 5d, black bars) and GE11 cisplatin micelles (Figure 5e, black
bars) showed a trend towards increasing the cytotoxicity of cisplatin, although the results were not
statistically significant.
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Figure 5. Dual pharmacological inhibition of signal transducer and activator of transcription 3 
(STAT3) and hypoxia inducing factor-1 (HIF-1) in combination with free cisplatin or its micellar 
formulations successfully reversed hypoxia-induced chemoresistance. (a) Lower expression of 
pSTAT3 in MDA-MB-231 cells after treatment with STAT3 inhibitor (Stattic). Phosphorylation of 
STAT3 Tyr705 was analyzed by Western blot. (b–d) Viability of MDA-MB-231 cells was measured by 
MTT assay for cells which first pre-incubated with the HIF-1 inhibitor (named P1) (50 μM), the 
STAT3 inhibitor (Stattic) (2 μM) or both under normoxia for 4 h and then incubated under hypoxia 
for additional 48 h (b) in the absence of cisplatin or in the presence of 50 μM (c) free drug; (d) plain 
Figure 5. Dual pharmacological inhibition of si al transducer and activat r of transcription 3
(STAT3) and hypoxia inducing factor-1 (HIF-1) in co tion with free cisplatin or its micellar
formulations succe sfully revers d hypoxia-induced hemoresistance. (a) Lower expr ssion of pSTAT3
in MDA-MB-231 cells after treatment with STAT3 inhibitor (Stattic). Phosphorylation of STAT3 Tyr705
was analyzed by Western blot. (b–d) Viability of MDA-MB-231 cells was measured by MTT assay
for cells which first pre-incubated with the HIF-1 inhibitor (named P1) (50 µM), the STAT3 inhibitor
(Stattic) (2 µM) or both under normoxia for 4 h and then incubated under hypoxia for additional 48 h
(b) in the absence of cisplatin or in the presence of 50 µM (c) free drug; (d) plain cisplatin micelles and
(e) GE11 cisplatin micelles. (*) denotes a significant difference between compared groups (one-way
ANOVA with Tukey post-test, p < 0.05).
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Simultaneous co-treatment of cells with inhibitors of HIF-1 and STAT3 enhanced the cytotoxic
effects of free cisplatin (Figure 5c), plain cisplatin micelles (Figure 5d) and GE11 cisplatin micelles
(Figure 5e) in both normoxic and hypoxic MDA-MB-231 cells (one-way ANOVA with Tukey post-test,
p < 0.05). Simultaneous co-treatment of cells with inhibitors of HIF-1 and STAT3 was the most
effective approach in the reversal of HICR for free cisplatin as well its nano-formulations in this
study. Co-treatment of cells with inhibitors of HIF-1 and STAT3 increased cisplatin toxicity under
both conditions for all different drug formulations; the enhancement was more noticeable under
hypoxia. For example, there was a ∼3.51-fold increase of cytotoxicity under hypoxia versus ∼1.93
under normoxia for free drug, ∼2.42-fold increase of cytotoxicity under hypoxia versus ∼2.27 under
normoxia for plain cisplatin micelles, and ∼2.46-fold increase of cytotoxicity under hypoxia versus
∼1.97 under normoxia for GE11 cisplatin micelles. All the comparisons were made to cells treated
with the related formulation in the absence of the inhibitors. Overall, free drug showed the highest
cytotoxicity enhancement (∼3.51-fold increase) after co-treatment of cells with the inhibitor of HIF-1
and STAT3, following by GE11 cisplatin micelles (∼2.46-fold increase) and plain cisplatin micelles
(∼2.42-fold increase) under hypoxia; whereas the cytotoxicity enhancement was similar for all the
formulations under normoxia (∼2.05-fold increase).
In all of the above experiments, irrespective of the oxygen pressure under which the cells were
cultured, no significant difference between the cytotoxicity of free drug and micellar formulations was
observed. In addition, GE11 cisplatin micelles showed a similar profile of toxicity as compared to plain
cisplatin micelles in MDA-MB-231 cells.
4. Discussion
Hypoxia is widely known to be associated with chemoresistance in different types of solid
tumors [2,3] including TNBC [4,5]. The increase in the expression of HIF-1α has long been associated
with the development of chemoresistance [4]. More recently, an increase in the activation of STAT3
following hypoxia is shown to be at least partly responsible for mediating chemoresistance in the
human ovarian cancer (i.e., A270 cells) and TNBC (i.e., MDA-MB-231 cells) [3,30]. Overexpression of
epidermal growth factor receptor (EGFR) and tumor hypoxia have also been shown to correlate with
worse outcomes in several types of cancers including breast cancer [16,44]. This coexistence of hypoxia
and EGFR may implicate a survival advantage of hypoxic cells that also express EGFR.
Design and development of nanotechnology products as a means to enhance the therapeutic
index of anticancer drugs has been explored intensely in the past few decades. In successful cases,
nano-formulations of anticancer drugs have shown to extend their blood circulation time leading to
improved accumulation of the drug in solid tumors mostly by the enhanced permeability and retention
(EPR) effect and/or decrease drug exposure and toxicity to normal tissues [9,45]. However, owing
to their nanoscopic size and slow drug release, nano-formulations of the anticancer drugs are also
speculated to provide limited access of the drug to hypoxic cancer cells that are located in areas of
tumor away from blood vessels [46].
The objective of this study was first to evaluate the cytotoxic behavior of a newly developed
nano-formulations of cisplatin on hypoxia-induced chemoresistant (HICR) MDA-MB-231 cells, a
TNBC cell line; and secondly to explore feasible approaches for overcoming HICR against free and
nano-formulations of cisplatin. For the latter purpose, we developed EGFR-targeted cisplatin micelles
using an EGFR-ligand, GE11 peptide and investigated the effect of combination therapy with inhibitors
of HIF-1 and STAT3 as the key mediators of HICR in this cell line.
Similar to plain cisplatin micelles, the GE11 cisplatin micelles showed slightly accelerated drug
release in an acidic environment (Figure 1b). The ability of acid-triggered release of these micelles
is important; tumors, particularly those with hypoxic regions, usually have lower extracellular pH
than that of normal tissues [47]. In this case, the acid-triggered release of cisplatin from the micellar
formulations may encourage drug release from the nano-formulation in the hypoxic tumor. This may
compensate for the restrictions faced by these nano-formulations for penetrating the tumor core. It is
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of note that this feature, i.e., the acid-triggered release of cisplatin from its micellar formulations, was
not investigated in our cell cytotoxicity studies as the pH of the cell culture media was maintained
at 7.4.
In concert with our previous study [30], we found that hypoxia significantly induced resistance
against free cisplatin in MDA-MB-231 cells (Figures 2 and 3a). MDA-MB-231 cells also showed
similar resistance against nano-formulations of cisplatin under hypoxia (Figure 3b,c). GE11 cisplatin
micelles showed increased intra-cellular levels of cisplatin compared to free and plain cisplatin micelles
under hypoxia, reaching intracellular cisplatin levels similar to that of the free drug under normoxic
conditions (Figure 4b). EGF receptors (EGFR) are internalizing receptors [48] with GE11 peptide as
their ligand [29]. Thus, surface modification of cisplatin micelles with the GE11 peptide in this study
was made to compensate for lower uptake of cisplatin under hypoxic conditions in MDA-MB-231 cells
expressing high levels of EGFR. The upregulation of ATP-binding cassette (ABC) drug transporters,
particularly ABCC2 and ABCC6, has been shown as one of the possible mechanisms responsible for
active efflux of free cisplatin under hypoxia in MDA-MB-231 cells, which subsequently contributes to
a decrease in the cellular levels of free cisplatin in this cell line [30]. Thus, the GE11 modified micelles
have a potential to bypass ABC-transporter mediated drug efflux.
In spite of enhanced intracellular cisplatin levels by the GE11 modified micelles, cytotoxicity of
cisplatin as part of GE11 micelles was not improved over plain cisplatin micelles, and both formulations
showed similar cytotoxicity in MDA-MB-231 cells under normoxic and hypoxic conditions. In addition,
irrespective of the oxygen pressure under which the cells were cultured, no significant difference
between the cytotoxicity of free drug and micellar formulations was observed. We are speculating two
reasons for this observation: (a) release of cisplatin from micelles at > 24 h incubation of micelles with
the cells have contributed to the similar profile of toxicity between free drug and micellar formulations;
(b) the increased level of cell uptake for cisplatin by GE11 cisplatin micelles is not enough to pass the
threshold required for bypassing the mechanisms of cisplatin resistance. More thorough studies are
required to elucidate the reason, which will be the subject of our future investigations.
The master regulator of cellular adaptation under hypoxia is believed to be the hypoxia-inducible
factor (HIF) protein [47,49]. HIF is a heterodimeric transcription factor comprised of an
oxygen-regulated unit, HIF-1α, as well as a constitutively expressed beta unit, HIF-1β. In the presence
of oxygen, once HIF-1α is produced; it will be hydroxylated, ubiquitinated, and degraded. In contrast,
in the absence of oxygen, HIF-1α is stabilized, dimerizes with HIF-1β, and the HIF heterodimers
translocate to the nucleus where it activates the transcription of various downstream targets, many of
which are known to be involved in cancer aggressiveness and chemoresistance [47,49,50]. The HIF-1
inhibitor used in our study (P1) specifically inhibits HIF-1α dimerization with HIF-1β and subsequently
inhibits HIF-1 transcription factor activity [39]. Our results showed that the combination of P1 with
cisplatin significantly enhanced cisplatin toxicity under hypoxia; however, it was not effective under
normoxic conditions. Co-treatment of cells with the HIF-1 inhibitor resulted in similarly enhanced
cytotoxicity for all cisplatin formulations under hypoxia as compared to cells treated with the related
formulation in the absence of inhibitor. The effectiveness of combination therapy under hypoxia is
likely due to the higher expression of HIF-1α under hypoxia as compared to normoxic conditions.
When combining a STAT3 inhibitor (Stattic) with cisplatin treatment, we did not observe any
significant changes in the profile of cytotoxicity of cisplatin in MDA-MB-231 cells. This was unexpected
given the results of previous studies supporting a role for activation of STAT3 in conferring HICR to
cisplatin [3,30], and the effectiveness of STAT3 siRNA in sensitization of MDA-MB-231 cells to cisplatin.
The exact reason behind the discrepancy is not clear and warrants further investigation. The efficiency
of inhibition of STAT3 activation may be varied following siRNA transfection versus Stattic treatment
at applied doses. The difference in the expression levels of pSTAT3 and its downstream targets involved
in aggressiveness and chemoresistance of cancer cells (e.g., c-Myc [51]) following STAT3 siRNA versus
Stattic treatment is speculated to have a role in this observation (Figure S5).
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It should be noted that some cancer cells, including MDA-MB-231 cells, constitutively express
high levels of HIF-1α [52] and pSTAT3 [53] under normal oxygen conditions, although their levels of
expression are significantly lower as compared to hypoxia. The inhibition of HIF-1 or STAT3, alone,
was not effective in enhancing the cytotoxic effect of cisplatin in our study under normoxic conditions.
However, when HIF-1 and STAT3 both were inhibited, the cytotoxic effects of cisplatin increased under
both normoxic and hypoxic conditions.
Previous studies have also provided support for the combined targeting of HIF-1 and STAT3 under
hypoxia for enhancing anti-tumor activity. For instance, administration of a series of dual inhibitors
of HIF-1α and STAT3 (in the absence of anticancer agent) resulted in significant anti-proliferative
activity across a panel of various cancer cell lines [54]. Furthermore, it has been shown that the
combination of other pharmacological inhibitors of HIF-1α and STAT3 enhanced prostate tumor
growth suppression [55]. The results of our study, however, provide proof-of-principle for the use of
HIF-1 and STAT3 inhibitors (individually or in combination) for sensitization of resistant cells under
hypoxia to cisplatin and its micellar formulations in TNBC. Our present efforts for combination therapy
are made by separate addition of inhibitors and cisplatin micelles in-vitro. Addition of inhibitors
to the cell culture medium was done a few hours before the treatment with cisplatin or its micellar
formulations. This approach was expected to provide enough time for the inhibitors to execute their
inhibitory effect and sensitize the cells to the treatment. However, moving forward to in-vivo studies,
delivery of both inhibitors and cisplatin within the same or separate micellar formulation can be
explored. The use of nanodelivery systems for drugs is expected to provide a control over the time
and extent of their delivery in solid tumors, maximizing their benefit
5. Conclusions
In summary, we have shown that the modification of cisplatin micelles with EGFR ligand
(i.e., GE11 peptide) compensated for the hypoxia-mediated reduced cisplatin uptake, although this
approach was not successful in increasing the levels of cytotoxicity of the drug. Importantly, our
findings suggest that the potency of conventional (i.e., cisplatin) and nano-formulations (i.e., cisplatin
micelles) can be enhanced under hypoxia once inhibitors of major cellular and molecular players of
hypoxia-induced chemoresistance (i.e., HIF-1 and STAT3) were used in combination. To conclude, we
have provided evidence to support that the rational therapeutic drug combination of sensitizing drugs
with other therapies should be used to overcome drug resistance.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/10/4/196/s1,
Figure S1. (a) GE11 peptide structure and (b) MALDI-MS spectrum of GE11 peptide, Figure S2. Monitoring
GE11 peptide conjugation to acetal-PEO-PCCL polymers using HPLC with UV detection at 214 nm, Figure S3.
The conjugation of GE11 peptide onto acetal-PEO-PCCL was confirmed by 1H-NMR spectra of block copolymer
before and after peptide conjugation. Samples (3–5 mg/mL) of acetal-PEO-PCCL and GE11-PEO-PCC were
prepared in DMSO for 1H NMR analysis, Figure S4. Bar graph illustrating quantification of the Western blot
densitometry analysis for Figure 5A. Densitometry data are expressed as fold changes compared to untreated
normoxic group, normalized to GAPDH band intensity, Figure S5. The chosen experimental model for inhibition
of STAT3 activation, STAT3 siRNA transfection versus pharmacological inhibition by Stattic, may result in different
levels of expression of STAT3 and/or its downstream targets such as c-Myc protein. The differential levels of
protein expression in MDA-MB-231 cells after transfection with STAT3 siRNA or treatment with Stattic (2µM) for
24 to 48 hours under hypoxia is depicted by Western blot.
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